Trial Profile
A Phase III, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of different schedules and formulations of a meningococcal A conjugate vaccine administered concomitantly with local EPI vaccines in healthy infants and toddlers.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2020
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group A conjugate (Primary)
- Indications Meningococcal group A infections; Meningococcal meningitis
- Focus Biomarker; Pharmacodynamics
- Sponsors Serum Institute of India
- 19 Nov 2020 Results of secondary analysis from four clinical studies: PsATT-002, PsATT-003, PsATT-004 and PsATT-007 assessing safety and efficacy in children in African meningitis belt published in the Vaccine
- 16 Jan 2014 Status changed from active, no longer recruiting to completed (closed to recruitment: follow up complete) as reported by Pan-African Clinical Trials Registry record.
- 24 Nov 2011 New trial record